4.7 Article

Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles

Journal

PHARMACEUTICS
Volume 12, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics12111004

Keywords

protein nanomaterials; functional materials; self-assembling nanoparticles; fluorescent labeling; biodistribution; targeting

Funding

  1. Agencia Estatal de Investigacion (AEI) [BIO2016-76063-R, PID2019-105416RB-I00]
  2. Fondo Europeo de Desarrollo Regional (FEDER) [BIO2016-76063-R, PID2019-105416RB-I00]
  3. AGAUR [2018FI_B2_00051, 2017 SGR 865 GRC]
  4. CIBER-BBN
  5. ISCIII (FEDER) [PIE15/00028, PI18/00650]
  6. FMMA [AP1666942017]
  7. ISCIII [PI17/00150]
  8. VI National R&D&I Plan 2008-2011
  9. Iniciativa Ingenio 2010
  10. Consolider Program
  11. CIBER Actions
  12. Instituto de Salud Carlos III from the European Regional Development Fund
  13. Miguel Servet contracts from ISCIII - European Social Fund (ESF investing in your future) [CP19/00028, CP15/00163]
  14. Government of Navarra
  15. Ministerio de Ciencia, Innovacion y Universidades [FPU18/04615]
  16. ICREA ACADEMIA award.

Ask authors/readers for more resources

Fluorescent dye labeling is a common strategy to analyze the fate of administered nanoparticles in living organisms. However, to which extent the labeling processes can alter the original nanoparticle biodistribution has been so far neglected. In this work, two widely used fluorescent dye molecules, namely, ATTO488 (ATTO) and Sulfo-Cy5 (S-Cy5), have been covalently attached to a well-characterized CXCR4-targeted self-assembling protein nanoparticle (known as T22-GFP-H6). The biodistribution of labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles has been then compared to that of the non-labeled nanoparticle in different CXCR4+ tumor mouse models. We observed that while parental T22-GFP-H6 nanoparticles accumulated mostly and specifically in CXCR4+ tumor cells, labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles showed a dramatic change in the biodistribution pattern, accumulating in non-target organs such as liver or kidney while reducing tumor targeting capacity. Therefore, the use of such labeling molecules should be avoided in target and non-target tissue uptake studies during the design and development of targeted nanoscale drug delivery systems, since their effect over the fate of the nanomaterial can lead to considerable miss-interpretations of the actual nanoparticle biodistribution.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available